Affimed N.V

General information
Affimed N.V
Im Neuenheimer Feld 582
Technologiepark
69120 Heidelberg, Baden-Württemberg
Germany

Contact person: Andreas Harstrick, Interim Chief Executive Officer. Chief Medical Off
Company main phone: +49 (6221) 674360
Company main fax:  +49 (6221) 6743649
Website:  https://www.affimed.com
Year founded:2000
Source of foundation:Spin-off from public institution / NPO
Name of foundation source:German Cancer Research Centre (DKFZ)
No. of employees: Worldwide:  76
Corporate description / mission:
Affimed is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK® platform predictably generates customized innate cell engager (ICE®) molecules, which use patients’ immune cells to destroy tumor cells.
State of ownership: Publicly listed on stock exchange
Headquarters: HQ: Yes
IPO (year): 2014
Categorization
Sector:
  • Biotechnology - Therapeutics and Diagnostics
Subsector:
  • Antibodies
  • Cell therapy
  • Immunotherapy
Primary therapeutic areas:
  • Neoplasms / cancer / oncology
Business model:
  • Out-licensing
  • R&D
Customer segments:
  • Large biotech & big pharma
  • Small biotech
Summary Products / Services / Technologies
Number of Biotech Products
Pre-clinical:4
Phase I:2
Phase II:6
Description of products:
AFM13
AFM24
AFM28
AFM32, etc.
Technology used:
ROCK® Platform
Financing details
Fiscal year (end of) 2023
Revenues:USD 8.95M
R&D expenses:USD 102.74M
Cash:USD 41.69M
Total liabilities:USD 42.58M
No. of shares:15'227'500
Market cap. / valuation:USD 89.39M
Collaborations & Clients
Partnering strategy / collaborations:
Genentech
Artiva
Roche
Merck, etc.
X